Abstract
Objective and design
The human c2orf40 gene encodes a tumor suppressor gene called esophageal cancer-related gene-4 (ECRG4) with pro- and anti-inflammatory activities that depend on cell surface processing. Here, we investigated its physical and functional association with the innate immunity receptor complex.
Methods
Interactions between ECRG4 and the innate immunity receptor complex were assessed by flow cytometry, immunohistochemistry, confocal microscopy, and co-immunoprecipitation. Phage display was used for ligand targeting to cells that overexpress the TLR4–MD2–CD14.
Results
Immunoprecipitation and immunohistochemical studies demonstrate a physical interaction between ECRG4 and TLR4–MD2–CD14 on human granulocytes. Flow cytometry shows ECRG4 on the cell surface of a subset of CD14+ and CD16+ leukocytes. In a cohort of trauma patients, the C-terminal 16 amino acid domain of ECRG4 (ECRG4133–148) appears to be processed and shed, presumably at a thrombin-like consensus sequence. Phage targeting this putative ligand shows that this peptide sequence internalizes into cells through the TLR4/CD14/MD2 complex, but modulates inflammation through non-canonical, NFκB signal transduction.
Conclusions
ECRG4 is present on the surface of human monocytes and granulocytes. Its interaction with the human innate immunity receptor complex supports a role for cell surface activation of ECRG4 during inflammation and implicates this receptor in its mechanism of action.
Similar content being viewed by others
References
Mirabeau O, Perlas E, Severini C, Audero E, Gascuel O, Possenti R, et al. Identification of novel peptide hormones in the human proteome by hidden Markov model screening. Genome Res. 2007;17(3):320–7. doi:10.1101/gr.5755407.
Ozawa A, Lick AN, Lindberg I. Processing of proaugurin is required to suppress proliferation of tumor cell lines. Mol Endocrinol. 2011;25(5):776–84. doi:10.1210/me.2010-0389.
Dang X, Podvin S, Coimbra R, Eliceiri B, Baird A. Cell-specific processing and release of the hormone-like precursor and candidate tumor suppressor gene product, Ecrg4. Cell Tissue Res. 2012;348(3):505–14. doi:10.1007/s00441-012-1396-6.
Podvin S, Gonzalez AM, Miller MC, Dang X, Botfield H, Donahue JE, et al. Esophageal cancer related gene-4 is a choroid plexus-derived injury response gene: evidence for a biphasic response in early and late brain injury. PLoS One. 2011;6(9):e24609. doi:10.1371/journal.pone.0024609.
Baird A, Coimbra R, Dang X, Lopez N, Lee J, Krzyzaniak M, et al. Cell surface localization and release of the candidate tumor suppressor Ecrg4 from polymorphonuclear cells and monocytes activate macrophages. J Leukoc Biol. 2012;91(5):773–81. doi:10.1189/jlb.1011503.
Su T, Liu H, Lu S. Cloning and identification of cDNA fragments related to human esophageal cancer. Zhonghua Zhong Liu Za Zhi. 1998;20(4):254–7.
Matsuzaki J, Torigoe T, Hirohashi Y, Tamura Y, Asanuma H, Nakazawa E, et al. Expression of ECRG4 is associated with lower proliferative potential of esophageal cancer cells. Pathol Int. 2013;63(8):391–7. doi:10.1111/pin.12079.
Mori Y, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Kurehara H, et al. Expression of ECRG4 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Oncol Rep. 2007;18(4):981–5.
Yue CM, Deng DJ, Bi MX, Guo LP, Lu SH. Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol. 2003;9(6):1174–8.
Wang YB, Ba CF. Promoter methylation of esophageal cancer-related gene 4 in gastric cancer tissue and its clinical significance. Hepatogastroenterology. 2012;59(118):1696–8. doi:10.5754/hge12258.
Li W, Liu X, Zhang B, Qi D, Zhang L, Jin Y, et al. Overexpression of candidate tumor suppressor ECRG4 inhibits Gliomas proliferation and invasion. J Exp Clin Cancer Res. 2010;29(1):89. doi:10.1186/1756-9966-29-89.
Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, et al. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest. 2009;27(5):549–60. doi:10.1080/07357900802620794.
Lee J, Dang X, Borboa A, Coimbra R, Baird A, Eliceiri BP. Thrombin-processed Ecrg4 recruits myeloid cells and induces antitumorigenic inflammation. Neuro Oncol. 2014. doi:10.1093/neuonc/nou302.
Baird A, Lee J, Podvin S, Kurabi A, Dang X, Coimbra R et al. Esophageal-Cancer-Related Gene-4 (ECRG4) at the Interface of Injury, Inflammation, Infection and Malignancy. Gastrointestinal Cancer: Targets and Therapy. 2014;4:131–42.
Huh YH, Ryu JH, Shin S, Lee DU, Yang S, Oh KS, et al. Esophageal cancer related gene 4 (ECRG4) is a marker of articular chondrocyte differentiation and cartilage destruction. Gene. 2009;448(1):7–15. doi:10.1016/j.gene.2009.08.015.
Kujuro Y, Suzuki N, Kondo T. Esophageal cancer-related gene 4 is a secreted inducer of cell senescence expressed by aged CNS precursor cells. Proc Natl Acad Sci USA. 2010;107(18):8259–64. doi:10.1073/pnas.0911446107.
Kurabi A, Pak K, Dang X, Coimbra R, Eliceiri BP, Ryan AF, et al. Ecrg4 attenuates the inflammatory proliferative response of mucosal epithelial cells to infection. PLoS One. 2013;8(4):e61394. doi:10.1371/journal.pone.0061394.
Shaterian A, Kao S, Chen L, DiPietro LA, Coimbra R, Eliceiri BP, et al. The candidate tumor suppressor gene Ecrg4 as a wound terminating factor in cutaneous injury. Arch Dermatol Res. 2013;305(2):141–9. doi:10.1007/s00403-012-1276-7.
Gonzalez AM, Podvin S, Lin SY, Miller MC, Botfield H, Leadbeater WE, et al. Ecrg4 expression and its product augurin in the choroid plexus: impact on fetal brain development, cerebrospinal fluid homeostasis and neuroprogenitor cell response to CNS injury. Fluids Barriers CNS. 2011;8(1):6. doi:10.1186/2045-8118-8-6.
Li LW, Yu XY, Yang Y, Zhang CP, Guo LP, Lu SH. Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer. 2009;125(7):1505–13. doi:10.1002/ijc.24513.
Sabatier R, Finetti P, Adelaide J, Guille A, Borg JP, Chaffanet M, et al. Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One. 2011;6(11):e27656. doi:10.1371/journal.pone.0027656.
Xu T, Xiao D, Zhang X. ECRG4 inhibits growth and invasiveness of squamous cell carcinoma of the head and neck and. Oncol Lett. 2013;5(6):1921–6. doi:10.3892/ol.2013.1298.
Balistreri CR, Colonna-Romano G, Lio D, Candore G, Caruso C. TLR4 polymorphisms and ageing: implications for the pathophysiology of age-related diseases. J Clin Immunol. 2009;29(4):406–15. doi:10.1007/s10875-009-9297-5.
Zhang K, Zhou B, Wang Y, Rao L, Zhang L. The TLR4 gene polymorphisms and susceptibility to cancer: a systematic review and meta-analysis. Eur J Cancer. 2013;49(4):946–54. doi:10.1016/j.ejca.2012.09.022.
Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett. 2009;14(2):248–72. doi:10.2478/s11658-008-0048-z.
Koller B, Bals R, Roos D, Korting HC, Griese M, Hartl D. Innate immune receptors on neutrophils and their role in chronic lung disease. Eur J Clin Invest. 2009;39(7):535–47. doi:10.1111/j.1365-2362.2009.02145.x.
Rallabhandi P, Bell J, Boukhvalova MS, Medvedev A, Lorenz E, Arditi M, et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol. 2006;177(1):322–32.
Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005;65(12):5009–14. doi:10.1158/0008-5472.can-05-0784.
Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, et al. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol. 2009;46(15):2876–84. doi:10.1016/j.molimm.2009.06.016.
Larocca D, Burg MA, Jensen-Pergakes K, Ravey EP, Gonzalez AM, Baird A. Evolving phage vectors for cell targeted gene delivery. Curr Pharm Biotechnol. 2002;3(1):45–57.
Holtta M, Zetterberg H, Mirgorodskaya E, Mattsson N, Blennow K, Gobom J. Peptidome analysis of cerebrospinal fluid by LC-MALDI MS. PLoS One. 2012;7(8):e42555. doi:10.1371/journal.pone.0042555.
Chank C, DM H, C S. Clinical proteomics analysis of the human serum proteome. NCI Large Human Serum Survey. 2012.
Calvano JE, Agnese DM, Um JY, Goshima M, Singhal R, Coyle SM, et al. Modulation of the lipopolysaccharide receptor complex (CD14, TLR4, MD-2) and toll-like receptor 2 in systemic inflammatory response syndrome-positive patients with and without infection: relationship to tolerance. Shock. 2003;20(5):415–9. doi:10.1097/01.shk.0000092269.01859.44.
Antal-Szalmas P, Strijp JA, Weersink AJ, Verhoef J, Van Kessel KP. Quantitation of surface CD14 on human monocytes and neutrophils. J Leukoc Biol. 1997;61(6):721–8.
Burg MA, Jensen-Pergakes K, Gonzalez AM, Ravey P, Baird A, Larocca D. Enhanced phagemid particle gene transfer in camptothecin-treated carcinoma cells. Cancer Res. 2002;62(4):977–81.
Larocca D, Jensen-Pergakes K, Burg MA, Baird A. Gene transfer using targeted filamentous bacteriophage. Methods Mol Biol. 2002;185:393–401.
Larocca D, Jensen-Pergakes K, Burg MA, Baird A. Receptor-targeted gene delivery using multivalent phagemid particles. Mol Ther. 2001;3(4):476–84. doi:10.1006/mthe.2001.0284.
Satta N, Kruithof EK, Fickentscher C, Dunoyer-Geindre S, Boehlen F, Reber G, et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. Blood. 2011;117(20):5523–31. doi:10.1182/blood-2010-11-316158.
Naka T, Nakata N, Maeda S, Yamamoto R, Doe M, Mizuno S, et al. Structure and host recognition of serotype 13 glycopeptidolipid from Mycobacterium intracellulare. J Bacteriol. 2011;193(20):5766–74. doi:10.1128/jb.05412-11.
Xu J, Zhang X, Monestier M, Esmon NL, Esmon CT. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol. 2011;187(5):2626–31. doi:10.4049/jimmunol.1003930.
Yang H, Young DW, Gusovsky F, Chow JC. Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4. MD-2 is required for activation of mitogen-activated protein kinases and Elk-1. J Biol Chem. 2000;275(27):20861–6. doi:10.1074/jbc.M002896200.
Espevik T, Latz E, Lien E, Monks B, Golenbock DT. Cell distributions and functions of Toll-like receptor 4 studied by fluorescent gene constructs. Scand J Infect Dis. 2003;35(9):660–4.
Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 1999;274(16):10689–92.
Kramer HK, Onoprishvili I, Andria ML, Hanna K, Sheinkman K, Haddad LB, et al. Delta opioid activation of the mitogen-activated protein kinase cascade does not require transphosphorylation of receptor tyrosine kinases. BMC Pharmacol. 2002;2:5.
Shah BH, Neithardt A, Chu DB, Shah FB, Catt KJ. Role of EGF receptor transactivation in phosphoinositide 3-kinase-dependent activation of MAP kinase by GPCRs. J Cell Physiol. 2006;206(1):47–57. doi:10.1002/jcp.20423.
Derrien A, Druey KM. RGS16 function is regulated by epidermal growth factor receptor-mediated tyrosine phosphorylation. J Biol Chem. 2001;276(51):48532–8. doi:10.1074/jbc.M108862200.
Soehnlein O, Lindbom L, Weber C. Mechanisms underlying neutrophil-mediated monocyte recruitment. Blood. 2009;114(21):4613–23. doi:10.1182/blood-2009-06-221630.
Kumar V, Sharma A. Neutrophils: Cinderella of innate immune system. Int Immunopharmacol. 2010;10(11):1325–34. doi:10.1016/j.intimp.2010.08.012.
Lederer JA, Brownstein BH, Lopez MC, Macmillan S, Delisle AJ, Macconmara MP, et al. Comparison of longitudinal leukocyte gene expression after burn injury or trauma-hemorrhage in mice. Physiol Genomics. 2008;32(3):299–310. doi:10.1152/physiolgenomics.00086.2007.
Pillay J, Ramakers BP, Kamp VM, Loi AL, Lam SW, Hietbrink F, et al. Functional heterogeneity and differential priming of circulating neutrophils in human experimental endotoxemia. J Leukoc Biol. 2010;88(1):211–20. doi:10.1189/jlb.1209793.
Kopydlowski KM, Salkowski CA, Cody MJ, van Rooijen N, Major J, Hamilton TA, et al. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J Immunol. 1999;163(3):1537–44.
Romero CD, Varma TK, Hobbs JB, Reyes A, Driver B, Sherwood ER. The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection. Infect Immun. 2011;79(9):3576–87. doi:10.1128/iai.00022-11.
Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal. 2001;13(2):85–94.
Xia Y, Yamagata K, Krukoff TL. Differential expression of the CD14/TLR4 complex and inflammatory signaling molecules following i.c.v. administration of LPS. Brain Res. 2006;1095(1):85–95. doi:10.1016/j.brainres.2006.03.112.
Ye Y, Xu H, Zhang X, Li Z, Jia Y, He X, et al. Association between toll-like receptor 4 expression and neural stem cell proliferation in the hippocampus 25 following traumatic brain injury in mice. Int J Mol Sci. 2014;15(7):12651–64. doi:10.3390/ijms150712651.
Chakravarty S, Herkenham M. Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J Neurosci. 2005;25(7):1788–96. doi:10.1523/jneurosci.4268-04.2005.
Wang J, Hori K, Ding J, Huang Y, Kwan P, Ladak A, et al. Toll-like receptors expressed by dermal fibroblasts contribute to hypertrophic scarring. J Cell Physiol. 2011;226(5):1265–73. doi:10.1002/jcp.22454.
Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7(3):179–90. doi:10.1038/nri2038.
Fu Y, Glaros T, Zhu M, Wang P, Wu Z, Tyson JJ, et al. Network topologies and dynamics leading to endotoxin tolerance and priming in innate immune cells. PLoS Comput Biol. 2012;8(5):e1002526. doi:10.1371/journal.pcbi.1002526.
Glezer I, Lapointe A, Rivest S. Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries. FASEB J. 2006;20(6):750–2. doi:10.1096/fj.05-5234fje.
Acknowledgments
The authors are indebted to Tran Nguyen, Emelie Amburn and Alexandra Ortiz-Borboa for expert technical assistance. Research was supported by a Mentored Young Investigator Award from the Hydrocephalus Association (S.P.), the National Institutes of Health through a P20 Exploratory Center grant for Wound Healing Research from the NIGMS (P20-GM078421) to A.B. and from grants EY018479 (A.B.), DK085871 (A.B.) and HL73396 (B.P.E.) and supplemental funding by the National Eye Institute (NEI) and NIGMS through the American Recovery Act (ARRA). Studies with human blood were funded by a grant from the American Burn Association (RC).
Author information
Authors and Affiliations
Corresponding author
Additional information
Responsible Editor: Liwu Li.
Rights and permissions
About this article
Cite this article
Podvin, S., Dang, X., Meads, M. et al. Esophageal cancer-related gene-4 (ECRG4) interactions with the innate immunity receptor complex. Inflamm. Res. 64, 107–118 (2015). https://doi.org/10.1007/s00011-014-0789-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-014-0789-2